Nurix Therapeutics, Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from 2019 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Nurix Therapeutics, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2019 to 2023.
- Nurix Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending August 31, 2024 was -$48.5M, a 33.5% decline year-over-year.
- Nurix Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending August 31, 2024 was -$175M, a 20% decline year-over-year.
- Nurix Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$140M, a 23.8% increase from 2022.
- Nurix Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$184M, a 56.1% decline from 2021.
- Nurix Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$118M, a 173% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)